Insmed jumps after forecasting preliminary 2025 revenue above estimates
Shares of drugmaker Insmed INSM.O rise 11.6% to $190 premarket
INSM expects 2025 revenue to be $606.4 million, compared to analysts' estimates of $513.5 million - data compiled by LSEG
Leerink Partners says Insmed blew consensus estimates out of the water "for the first full quarter of Brinsupri's launch, with sales of $144.6 million"
Brinsupri was approved by U.S. FDA in August 2025 to treat type of lung disease called non-cystic fibrosis bronchiectasis
Expects 2025 revenue for its lead drug, Arikayce, to be 433.8 million vs estimates of $428.3 million
Expects 2026 revenue for Arikayce to be between $450 million and $470 million, compared to estimates of $499.1 million
"The actual results could be materially different from these preliminary unaudited financial results" - INSM
"This launch is still in the early innings, and we remain positive on this story for not only Brinsupri but the suite of catalysts expected over the next 12+ months," Leerink adds
As of last close, stock has more than doubled in past 12 months
Related Articles
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first t
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
